)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
Rigel Pharmaceuticals (RIGL) investor relations material
Rigel Pharmaceuticals Corporate Presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate Presentation summary7 Dec, 2025
Commercial performance and portfolio growth
Net product sales for Q3 2025 reached $64.1M, with TAVALISSE at $44.7M, GAVRETO at $11.1M, and REZLIDHIA at $8.3M, all showing strong year-over-year growth.
2025 net product sales guidance was raised to $225M–$230M, reflecting 55–59% growth and a 32% CAGR since 2021.
Global expansion includes commercial launches and regulatory approvals for TAVALISSE and REZLIDHIA in multiple international markets.
Collaboration revenues in Q3 2025 totaled $5.4M, with key partners including Grifols, Kissei, and Medison.
Total 2025 revenue is projected at $285M–$290M, with continued positive net income expected.
Product and clinical development highlights
TAVALISSE is indicated for chronic immune thrombocytopenia (CITP) and demonstrated efficacy across multiple lines of therapy, with a favorable safety profile.
REZLIDHIA is approved for relapsed/refractory AML with susceptible IDH1 mutation, showing a 35% CR+CRh rate and durable responses in a Phase 2 trial.
GAVRETO is approved for RET fusion-positive NSCLC and thyroid cancer, offering once-daily oral dosing and high response rates.
R289, a dual IRAK1/4 inhibitor, is in Phase 1b for lower-risk MDS, with Fast Track and Orphan Drug designations and promising early efficacy and safety data.
Strategic collaborations are advancing olutasidenib in AML, MDS, and glioma, with multiple ongoing studies and new indications under evaluation.
Financial and strategic outlook
Cash, cash equivalents, and short-term investments were $137.1M as of September 30, 2025.
The company is pursuing late-stage in-licensing and product acquisition opportunities to leverage existing capabilities.
Continued financial discipline is emphasized, with investment in both commercial and development programs.
The portfolio is positioned for further growth through expanded adoption, global access, and new clinical data presentations.
R289 registrational study timeline
Olutasidenib glioma market opportunity
RIPK1 CNS program termination impact
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Rigel Pharmaceuticals earnings date
Q4 20253 Mar, 2026
Next Rigel Pharmaceuticals earnings date
Q4 20253 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Rigel Pharmaceuticals Inc. is a biotechnology company focused on discovering, developing, and commercializing small-molecule drugs for immune and hematologic disorders, as well as rare diseases. The company’s research and development efforts target critical pathways in the immune system to address conditions with significant unmet medical needs. Rigel also partners with other pharmaceutical companies to advance its therapeutic candidates. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage